I have a few questions for the authors: 1. Is this data relevant outside of Taiwan? 2. When the authors discuss quartiles "Q", it should be better defined what this is a quartile of. 3. Changes in chemotherapy regimen are rarely undertaken without recurrent disease in the adjuvant setting. How reliable to the authors believe their recurrence data is for patients changing chemotherapy regimens? 4. Did any of the surgeons have advanced oncology training? 5. In Taiwan, is the chemotherapy delivered in physician's offices or in a hospital or multispecialty clinic?
REVIEWER
Dr Pauline C Leonard Whittington Health NHS Trust UK REVIEW RETURNED 29-May-2018
GENERAL COMMENTS
I am unclear what this paper is truly trying to achieve as the conclusions drawn are not supported by the detail the reader needs to understand to draw a conclusion for e.g outcome was less favourable if changes were made to the chemo regimen. What does this mean? Dose reductions, changing from a doublet regimen to a single drug regimen? If on one hand it is saying if we get the selection criteria right for adjuvant treatment it doesn't matter of a medical oncologist tor surgeon oversees the care but then it makes references that surgeons make more changes so outcomes are inferior. The paper was too busy for me with multiple threads and no one good narrative to follow. The data charts lacked the detail I wanted to see re regimen changes. The number of patients receiving any adjuvant chemotherapy was 17% of the total patients who underwent colectomy so this seemed the cohort under represented the real population who would be considered for adjuvant chemo. I would have like to see the eligibility criteria for entry into each path rather than a reference to which guideline they were following.
REVIEWER

Allison Drosdowsky
Peter MacCallum Cancer Centre, Melbourne, Australia REVIEW RETURNED 17-Jul-2018
GENERAL COMMENTS -Overall, this is an interesting study that appears to answer an important question for healthcare provision in Taiwan. However, there are issues in the reporting of the study that make it difficult to ascertain how well this occurred.
-I can't find a clear statement of the objectives of this research within the main text of the manuscript. Without this, it is difficult to determine whether the methods and results are presented sufficiently. In general, the results have many comparisons that do not seem applicable to the general aim (comparing the differences between patients based on care path), for example presenting the effect of gender on recurrence by stage (page 9, line 25)
-The use of a propensity score matching technique is a good choice, however more information needs to be provided on this methodology. The attached paper by Yao et. al. contains guidelines for reporting on propensity score analyses and may be a useful reference. Specifically, information on the matching variables, matching technique including replacement, missingness and proportion of the final sample from the initial, etc. are needed to assess the suitability of your method.
-Related, the results (page 9, line 2) note that 'no differences were observed between patients receiving care from different professionals in terms of sex, age, disease stage, NCI score or adjuvant chemotherapy.' Were any of these variables involved in the matching procedure? We would not expect to see differences if they were.
-In text, the results (Page 8, line 47) count 3,534 patients eligible for the study, however the participant flow diagram lists 3,797 eligible patients for the matching procedure.
-The results report on patients whose 'progress was at the lower end of the spectrum (<Q1 and Q1 to median)' (page 9, line 8) without defining what this is or how it was calculated. The provided range (<Q1 and Q1 to median) suggests anyone below the median of an unknown measure was included, can these patients all really be categorised as 'the lower end of the spectrum'? The same applies for the subsequent lines about the 'upper end of the spectrum'. Without knowing what 'progress' is referring to, it is difficult to determine whether this analysis should be included-if 'progress' is related to DFS, the results of the proportional hazard model should be sufficient. If this is a post-hoc analysis after the non-significant findings of the models, in regards to care path vs DFS, this should be clearly stated in both the results and the methodology.
-The data used in this study are, in part, over a decade old. This should probably be discussed in the limitations section of the manuscript. The other limitations in this section are described very well.
- Table 1 Response: This study addresses the professional makeup of health-care systems. In countries with a clear demarcation between specialties, surgeons do not cross professional boundaries into the prescription of chemotherapy. As a result, cancer patients tend to follow a single treatment path. In countries lacking medical staff, surgeons often have no choice but to prescribe chemotherapy (Aju Mathew, Global Survey of Clinical Oncology Workforce. J Glob Onco 2018). The cross-boundary cancer care situation in Taiwan is unique, considering the abundance of well-trained oncologists and surgeons. We therefore acknowledge that our results are not generalizable to all other countries. Nonetheless, our results are applicable to other countries in which cross-boundary cancer care is the reality.
2.
When the authors discuss quartiles "Q", it should be better defined what this is a quartile of.
Response: The quartile of case volume was set at Q1 (25%): 379, Q2 (50%): 719, and Q3 (75%) with 1228 patients receiving surgery and/or chemotherapy in a given year. To reduce ambiguity, we have replaced the term Q with percentile (%) in the Results and Discussion section, as shown below:
(p7, line 17) "… in quartiles of case volume (i.e., < 25%, 25-50%, 51-75%, >75%)" (p8, line 18-20) "A greater proportion of patients received postoperative chemotherapy from low-volume surgeons than from low-volume oncologists (<25%: 34.0% vs 14.3%; 25-50%: 31.9% vs 17.1%, respectively, p < .0001)"
(p10, line 33-37) "In this study, the provider's patient volume was not associated with recurrence; however, we found that 65.9% of patients who received chemotherapy from surgeons were treated by professionals with low case volumes (<=50%). Conversely, we found that 68.5% of patients who received chemotherapy from oncologists were treated by professionals with high case volumes (>50%)."
3.
Changes in chemotherapy regimen are rarely undertaken without recurrent disease in the adjuvant setting. How reliable to the authors believe their recurrence data is for patients changing chemotherapy regimens?
Response: We thank Dr. Levine for bringing up this issue. Changes in treatment regimen may be initiated for any number of reasons, and are not necessarily limited to recurrent disease. These changes include the inclusion of new agents or the removal of old agents. A change could be a switch from intravenous to oral agent, or a switch between bolus and continuous treatment. Changes could involve a dose reduction, a shortening or extension of the treatment period, or adjustment to the number of cycles. We did not set out to characterize changes in treatment regimen. In fact, when we selected two examples from among all the variety of changes addressed in this study, we were surprised to observe a strong association with recurrence. We believe that this has important implications for clinical care. We also believe that this relationship with recurrence is worthy of further investigation. A change in regimens cannot be used as a proxy indicating a causal relationship; however, we conducted sensitivity analysis in which 221 patients who underwent a regimen change were excluded. Our results still showed no significant differences in recurrence between patients receiving chemotherapy from oncologists or from surgeons.
4.
Did any of the surgeons have advanced oncology training?
Response: The subspecialty of "Surgical Oncology" is a new program initiated and supervised by Taiwan Surgical Association since 2011 (http://www.surgery.org.tw/Dc_in). However, this program focuses on surgeons in upcoming generations, and should therefore have no influence on the treatment provided to patients who were diagnosed between 2005 and 2009.
5.
In Taiwan, is the chemotherapy delivered in physician's offices or in a hospital or multispecialty clinic?
Response: Most patients in Taiwan are treated in hospitals. Very few of the personnel working in physician's offices or multidisciplinary clinics have training in the delivery of chemotherapy. Furthermore, only hospitals that meet strict criteria are eligible to report data of newly diagnosed patients in long-form format (i.e., including cancer staging and information pertaining to the first course of treatment). This means that cancer patients who were not treated at reporting hospitals were not included in this study. Nonetheless, most patients who received their first course of treatment at a reporting hospital continued receiving care from the same hospital.
Reviewer #2, Dr. Pauline C Leonard 1.
I am unclear what this paper is truly trying to achieve as the conclusions drawn are not supported by the detail the reader needs to understand to draw a conclusion for e.g outcome was less favourable if changes were made to the chemo regimen. What does this mean? Dose reductions, changing from a doublet regimen to a single drug regimen? If on one hand it is saying if we get the selection criteria right for adjuvant treatment it doesn't matter of a medical oncologist tor surgeon oversees the care but then it makes references that surgeons make more changes so outcomes are inferior.
Response: We did indeed find that surgeons are more likely to change the treatment regimen than are oncologists; however, the difference was not statistically significant (p = .060). We also observed that the rate of disease recurrence among patients who undergo changes in their chemotherapy regimens (stage II, HR: 5.97, 95%CI: 2.98-11.97; stage III, HR: 2.49, 95% CI: 1.90-3.26) was higher than among those who did not undergo such changes. Nonetheless, our study design cannot be used to determine whether surgeons were more prone to changing the treatment regimens, or to characterize the outcomes in cases where changes were made. We included regimen changes in our statistical models to control for confounding factors related to regimen changes, which are not necessarily observable in our data. We also conducted sensitivity analysis that included only patients who had not undergone regimen changes (please see Appendix Table 1 below). Our results revealed no statistical difference in disease recurrence among patients treated by oncologists or surgeons. We thank you for reminding us of the other confounding factors related to chemotherapy, which we have addressed in the Limitations section (p11, line 25-33).
2.
The paper was too busy for me with multiple threads and no one good narrative to follow. The data charts lacked the detail I wanted to see re regimen changes.
Response: We apologize for the confusion. In the revised manuscript, we have focused more on the main goal of this study; i.e., comparing the outcomes between patients treated by oncologists and surgeons. We also conducted an additional comparison of the baseline characteristics of colon cancer between patients who did or did not undergo regimen changes (please see Appendix Table 2 below). However, as mentioned above, our objective in including regimen changes in our statistical models was primarily to control for confounding factors that are related to regimen changes but were not able to be observed in our data.
3.
The number of patients receiving any adjuvant chemotherapy was 17% of the total patients who underwent colectomy so this seemed the cohort under represented the real population who would be considered for adjuvant chemo.
Response: We assume this is a calculation derived from a total 3,534 out of 20,678 patients who underwent colectomy. The correct proportion of patients who underwent adjuvant chemotherapy should be 38.8% (8,015 out of 20,678).
4.
I would have like to see the eligibility criteria for entry into each path rather than a reference to which guideline they were following.
Response: This was a retrospective observational study; therefore, the assignment of patients to each path was based on information derived from claims data. This is the nature (and limitation) of observational studies; i.e., patients cannot be assigned randomly to each group. Unlike prospective randomized clinical trials, we did not have "eligibility criteria" by which to assign participants to the various different paths. Nonetheless, we adopted propensity score matching (PSM) to confront the issue of selection bias. The guidelines mentioned in the main text are based on an international consensus that patients should receive adjuvant chemotherapy based on pathologic staging and risk factors. This in no way influences the assignment ("guiding") of patients to any path. Overall, this is an interesting study that appears to answer an important question for healthcare provision in Taiwan. However, there are issues in the reporting of the study that make it difficult to ascertain how well this occurred.
Appendix
1.
I can't find a clear statement of the objectives of this research within the main text of the manuscript. Without this, it is difficult to determine whether the methods and results are presented sufficiently. In general, the results have many comparisons that do not seem applicable to the general aim (comparing the differences between patients based on care path), for example presenting the effect of gender on recurrence by stage (page 9, line 25)
Response: We would like to thank Ms. Drosdowsky for addressing this concern. We have revised the Introduction of the manuscript (p5, line 8) to clarify the objectives of the study. We agree that several of the comparisons were not in line with the objectives of this study. Those parts have been deleted.
2.
The use of a propensity score matching technique is a good choice, however more information needs to be provided on this methodology. The attached paper by Yao et. al. contains guidelines for reporting on propensity score analyses and may be a useful reference. Specifically, information on the matching variables, matching technique including replacement, missingness and proportion of the final sample from the initial, etc. are needed to assess the suitability of your method.
Response: We thank Dr. Drosdowsky' for her valuable feedback on the proposed PSM method and tables. We have revised the description of the statistical methods and provided additional information in the Materials and Methods section (p7, line 21-30).
Specifically, the variables used for matching included comorbidities selected by the NCI comorbidity index1, sex, age, stage of cancer, and history of regimen changes. No sampling or replacement was used in this study. Patients with missing information were excluded from analysis (as shown in Figure   1 .). Table 1 shows that a total of 3534 matched cases (93%) was included in this study. We did not observe statistically significant differences in the distribution of any matched variables except age between patents receiving chemotherapy from oncologists or surgeons. Other statistical details are elaborated in the Methods section.
3. Related, the results (page 9, line 2) note that 'no differences were observed between patients receiving care from different professionals in terms of sex, age, disease stage, NCI score or adjuvant chemotherapy.' Were any of these variables involved in the matching procedure? We would not expect to see differences if they were.
Response: We have excluded those descriptions from the revised manuscript.
4.
In text, the results (Page 8, line 47) count 3,534 patients eligible for the study, however the participant flow diagram lists 3,797 eligible patients for the matching procedure.
Response: We have revised the text as follows: "This left a total 3,534 "matched" patients eligible for
analysis." Please see the flowchart ( Fig. 1) and the text in the Results section (p 8, line 8).
5.
The results report on patients whose 'progress was at the lower end of the spectrum (<Q1 and Q1 to median)' (page 9, line 8) without defining what this is or how it was calculated. The provided range (<Q1 and Q1 to median) suggests anyone below the median of an unknown measure was included, can these patients all really be categorised as 'the lower end of the spectrum'? The same applies for the subsequent lines about the 'upper end of the spectrum'. Without knowing what 'progress' is referring to, it is difficult to determine whether this analysis should be included-if 'progress' is related to DFS, the results of the proportional hazard model should be sufficient. If this is a post-hoc analysis after the non-significant findings of the models, in regards to care path vs DFS, this should be clearly stated in both the results and the methodology.
Response: In this study, the term "progress" does not refer to the progression of colon cancer and is not related to any DFS. We have rewritten these paragraphs as follows: "A greater proportion of patients received postoperative chemotherapy from low-volume surgeons than from low-volume oncologists (<25%: 34.0% vs 14.3%; 25-50%: 31.9% vs 17.1% respectively, p < .0001)."
In the original manuscript, the term "performance" referred to the case volume of physicians.
Performance is categorized into four classes based on the cut-off points representing the interquartile range (IQR): 25% (n = 379), 50%, (n = 719), and 75%, (n = 1,228 patients). In the revised manuscript, we have adopted the term "provider case volume" to prevent misunderstanding. We have also used "<25%", "25-50%", "51-75%", and ">75%" to indicate the four classes. (p7, line 17).
6.
The data used in this study are, in part, over a decade old. This should probably be discussed in the limitations section of the manuscript. The other limitations in this section are described very well.
Response: We identified cancer patients using data from the Taiwan Cancer Registry. We linked data obtained from the Taiwan Cancer Registry to population-based National Health Insurance data. The design of the original study was meant to ensure a 5-year follow up for study sample. We were able to identify the patients diagnosed with cancer after 2009; however, at the time that the project was started, we were unable to obtain data from the National Health Insurance database after 2012. Response: We thank the reviewer for pointing out this error in analysis. We have re-run the analysis.
The statistical results before and after matching are listed in the revised Table 1 . Those characteristics were compared using the Mantel-Haenszel test for categorical variables and generalized estimating equations (GEE) regression for continuous variables. We have clarified this in the Material and
